Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma: Demonstrating Sustained Long-Term Overall Survival in Patients Treated with UV1 Cancer Vaccine
October 12, 2023 01:00 ET
|
Ultimovacs ASA
No confirmed patient deaths occurred in cohort 1 between the 3-year and 4-year follow-up. Oslo, October 12, 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage...
Ultimovacs Receives FDA Orphan Drug Designation for the UV1 Cancer Vaccine for Treatment of Mesothelioma
October 09, 2023 01:00 ET
|
Ultimovacs ASA
The orphan drug designation was granted based on data from the randomized Phase II clinical trial NIPU The results from the NIPU study will be presented at the ESMO Congress being held October...
Ultimovacs Announces that the Results from UV1 Phase II Clinical Trial NIPU in Malignant Mesothelioma will be Presented at the ESMO Congress 2023
September 27, 2023 10:31 ET
|
Ultimovacs ASA
The results from the NIPU study will be presented by the Principal Investigator as an oral presentation at the ESMO Congress 2023 in Madrid, Spain, 20-24 October 2023. Oslo, September 27, 2023 –...
Ultimovacs ASA Reports Second Quarter 2023 Financial Results and Provides General Business Update
August 22, 2023 02:00 ET
|
Ultimovacs ASA
Oslo, 22 August 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its second quarter 2023 results today. “In...
Ultimovacs ASA: Invitation to second quarter 2023 results webcast presentation
August 16, 2023 02:00 ET
|
Ultimovacs ASA
Oslo, 16 August 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, invites to a webcast presentation of its second...
Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of UV1 in Head and Neck Cancer Patients
August 03, 2023 02:00 ET
|
Ultimovacs ASA
The randomized, investigator-initiated FOCUS trial has completed enrollment of 75 patients with recurrent or metastatic head and neck squamous cell carcinoma The study will provide randomized data...
Ultimovacs Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results
June 28, 2023 10:30 ET
|
Ultimovacs ASA
Results from the UV1-103 trial published in Clinical Cancer Research highlight the promising efficacy and safety of UV1 and pembrolizumab in malignant melanoma Biomarker analyses demonstrate...
Ultimovacs’ Chief Scientific Officer Gustav Gaudernack Receives Norwegian Tech Award’s Honorary Prize as an Outstanding Pioneer Against Cancer
June 22, 2023 09:30 ET
|
Ultimovacs ASA
NON-REGULATORY PRESS RELEASE The Honorary Prize is awarded to an individual who has left a remarkable imprint and contributed with notable impact through their dedicated efforts and outstanding...
Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine
June 19, 2023 01:00 ET
|
Ultimovacs ASA
All patients in cohort 2 who were alive after 2 years remain alive after 3 years Oslo, 19 June 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology...
Ultimovacs ASA: Mandatory notification of trade by primary insider
June 08, 2023 08:34 ET
|
Ultimovacs ASA
Oslo, 08 June 2023, Board member Ketil Fjerdingen and primary insider in Ultimovacs ASA, has today through Langøya Invest AS bought 7,000 shares in the company at a price of NOK 79.5159 per share....